Leállítva1. fázis
Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
A legfontosabb adatok
- Ki végzi
- Novartis Pharmaceuticals
- Hol
- Chicago, Memphis és New York (Egyesült Államok)Mind a 3 helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1. fázis
- Résztvevők
- 4 fő vett részt
- Kezdés
- 2020. aug. 25.
- Befejezés
- 2025. jan. 6.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- OTQ923
- A regiszteradat frissítve
- 2026. január 8.
- Miért állt le
- The decision of early termination was made due to business reasons and was not a consequence of any safety concern.
Ki vehet részt
- Életkor
- 2 év – 40 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female subjects age 2-40 years inclusive
- Confirmed diagnosis of sickle cell disease with globin typing (e.g. HbSS, HbSC, HbS/β0-thalassemia or others)
- Performance status >70% (Karnofsky for subjects >16 years of age and Lansky for subjects <16 years of age)
- At least one of the following indicators of disease severity as defined in the protocol - Vaso-occlusive pain crisis, Acute chest syndrome, Recurrent priapism, prior stroke, receive chronic transfusions, Red cell alloimmunization
- Subjects, who have failed, not tolerated or refused hydroxyurea therapy
Ki nem vehet részt
- Prior HSCT or gene therapy
- Clinically significant active infection
- Seropositive for HIV or HTLV
- Active known malignancy, myelodysplasia, abnormal cytogenetics or immunodeficiency
- Known hepatic cirrhosis, bridging hepatic fibrosis or active hepatitis
- Severe or progressive arteriopathy or cerebrovascular disease, including Moyamoya; Other protocol defined inclusion/exclusion criteria may apply
- Available matched related donor for HSCT
- Protocol defined iron overload
- Cerebrovascular procedure within one year, including pial synangiosis for Moyamoya
Helyszínek itt: Egyesült Államok
- University of ChicagoChicago, Egyesült Államok
- St. Jude Children's Research HospitalMemphis, Egyesült Államok
- Memorial Sloan Kettering Cancer CtrNew York, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study evaluated a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.
A vizsgálat csoportja
- OTQ923A vizsgált kezelés
Single intravenous infusion of OTQ923 Part A - Adults treated with OTQ923; Part B - Children age 2-17 treated with OTQ923 based on review of data from Part A by Health agency after a formal interim analysis.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease
- Publikációk
- Future directions in transplantation for aplastic anemia.Hematology. American Society of Hematology. Education Program, 2025
- Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance.Transplantation and cellular therapy, 2024
- CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.The New England journal of medicine, 2023
- Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers.Pediatric blood & cancer, 2023
- Attitudes toward COVID-19 vaccine among pediatric patients with sickle cell disease and their caregivers.Pediatric blood & cancer, 2023
- Editing human hematopoietic stem cells: advances and challenges.Cytotherapy, 2023
- A regiszteradat frissítve
- 2026. január 8.